目录产品 » Kallikrein 5/KLK5, His, Human
Manual
SDS
COAs

Kallikrein 5/KLK5, His, Human

The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
￥3300
Z05543-100

产品简介
Species Human
Protein Construction
Kallikrein 5/KLK5 (Val23-Ser293)_x000D_
Accession # Q9Y337		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 95% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Immobilized Kallikrein 5/KLK5, His, Human at 0.5μg/ml (100μl/Well) on the plate can bind Anti­Kallikrein 5 Antibody, hFc Tag. Test result was comparable to standard batch. Measured by its ability to cleave the fluorogenic peptide substrate Boc­VPR­AMC. The specific activity is >200 pmol/min/µg. Test result was comparable to standard batch
Expression System HEK293
Theoretical Molecular Weight 30.7 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 42-48 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in 50mM MES, 150mM NaCl (pH 5.5).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in 50mM MES, 150mM NaCl (pH 5.5).
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background The inhibition of kallikrein 5 (KLK5) has been identified as a potential strategy for treatment of the genetic skin disorder Netherton syndrome, in which loss-of-function mutations in the SPINK5 gene lead to down-regulation of the endogenous inhibitor LEKTI-1 and profound skin-barrier defects with severe allergic manifestations. To aid in the development of a medicine for this target, an X-ray crystallographic system was developed to facilitate fragment-guided chemistry and knowledge-based drug-discovery approaches.
Synonyms Kallikrein c; Klnc; KLK5; KLKL2; KLK-L2; SCTE
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.